Last edition
News about Market
JB Pharma Q2 FY26 Net Profit Rises 19 Percent to INR 208 Crore
JB Chemicals & Pharmaceuticals reported a net profit of INR 208 crore for the quarter ended September 30, 2025, marking a 19 percent year-on-year increase from INR 175 crore in the same period last year.
Market | 12/11/2025 | By Darshana | 206
GENFIT and EVerZom Partner to Advance Exosome-based Regenerative Technology in ACLF
Under the collaboration, GENFIT and EVerZom will combine expertise to advance EViv, an exosome-based regenerative therapy for ACLF, with GENFIT leading preclinical evaluation and EVerZom providing its bioproduction platform. GENFIT also holds an exclusive option to licence the programme following successful proof-of-concept results.
Market | 12/11/2025 | By Dineshwori | 305
Glenmark Secures China's Approval For RYALTRIS
Glenmark Pharmaceuticals has received regulatory approval in China for RYALTRIS. Combining olopatadine hydrochloride and mometasone furoate, it offers dual-action relief from nasal symptoms, further strengthening Glenmark’s position as a global leader in respiratory innovation.
Market | 11/11/2025 | By Dineshwori | 705
FDA Approves DARZALEX Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma
The US FDA has approved DARZALEX Faspro as the first treatment for adult patients with High-Risk Smoldering Multiple Myeloma (HR-SMM), marking a key milestone in addressing this early stage of the disease.
Market | 11/11/2025 | By Dineshwori | 218
Organon Announces Agreement to Divest its JADA System for up to USD 465 Million to Laborie
Organon has entered into a definitive agreement to divest its JADA System to Laborie for up to USD 465 million. The deal aims to leverage Laborie’s expertise in medical technology to expand the reach of JADA, enhancing access to postpartum hemorrhage treatment for mothers worldwide.
Market | 11/11/2025 | By Dineshwori | 474
Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra in India
Under this agreement, Emcure becomes the first Indian company to hold exclusive rights for the distribution and commercialisation of the drug, expanding access to Novo Nordisk’s innovative semaglutide therapy for people living with overweight and obesity in the country.
Market | 10/11/2025 | By Dineshwori | 825
USFDA Approves Alembic Pharmaceuticals' Sumatriptan Single-Dose Autoinjector
Alembic Pharmaceuticals has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan single-dose autoinjector, deemed therapeutically equivalent to GlaxoSmithKline’s Imitrex STATdose System in 4 mg/0.5 mL and 6 mg/0.5 mL strengths.
Market | 10/11/2025 | By Dineshwori | 269
Mankind Pharma Q2 Net Profit Falls 21 Percent to INR 520 Crore
Mankind Pharma reported a 21 percent year-on-year decline in consolidated net profit for the quarter ended September 30, 2025, with profit falling to approximately INR 520 crore from INR 661 crore in the same period last year.
Market | 07/11/2025 | By Darshana | 254
Zydus Lifesciences reported a robust performance for the second quarter ended September 30, 2025, with net profit rising over 38 percent to INR 1,258.6 crore, compared to INR 911.2 crore in the same quarter last year.
Market | 06/11/2025 | By Darshana | 307
USFDA Grants ODD to Zydus' Desidustat for Beta-Thalassemia Treatment
Desidustat, a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), has received Orphan Drug Designation (ODD) from the USFDA. The designation grants eligibility for up to seven years of marketing exclusivity upon approval and highlights Desidustat’s potential to boost haemoglobin and red blood cell production.
Market | 06/11/2025 | By Dineshwori | 278
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy